ʻIke mākou i ka hana ʻana o ka lāʻau lapaʻau, i hui pū ʻia me nā olakino lehulehu a me nā hana pilikino, e hōʻemi i ka hoʻolaha ʻana o COVID-19 a me kāna mau ʻano. Eia naʻe, ʻo ka puka hou ʻana mai o ka ʻano Omicron he mea hoʻomanaʻo ʻaʻole i pau ka maʻi maʻi COVID-19 a ke noho nei mākou i kahi kaiāulu honua. Ma ke ʻano he Luna Lapaʻau Nui o ke Ola, ʻike mākou i ke koʻikoʻi o ke kaulike o ka honua i ka hāʻawi ʻana i ke kano a me ke kuleana o ka pono ʻole i ka puka ʻana o nā ʻano hou. ʻOiai mākou e aʻo hou aʻe e pili ana i kēia ʻano like ʻole, hiki iā mākou ke kōkua i ka mālama ʻana i kā mākou holomua hui ʻana ma o ka hoʻomau ʻana i nā papahana lapaʻau COVID-19 a me ka hahai ʻana i nā hoʻolālā olakino olakino i kūpono i ke kōkua ʻana i kēia maʻi maʻi.

Ma ke ʻano he Luna Lapaʻau Nui o ke Ola, ʻike mākou i ke koʻikoʻi o ke kaulike o ka honua i ka hāʻawi ʻana i ke kano a me ke kuleana o ka pono ʻole i ka puka ʻana o nā ʻano hou. ʻOiai mākou e aʻo hou aʻe e pili ana i kēia ʻano like ʻole, hiki iā mākou ke kōkua i ka mālama ʻana i kā mākou holomua hui ʻana ma o ka hoʻomau ʻana i nā papahana lapaʻau COVID-19 a me ka hahai ʻana i nā hoʻolālā olakino olakino i kūpono i ke kōkua ʻana i kēia maʻi maʻi.

Ke hoʻomau nei nā hōʻike ʻepekema, nā ʻikepili ulu a me nā ʻōlelo aʻo loea e hōʻike iā mākou i ka hoʻohana pono ʻana o nā kano COVID-19 i ʻae ʻia ma Kanada. Ua hoʻokuʻu hou ʻo NACI i nā ʻōlelo aʻoaʻo hou e pili ana i nā mea hoʻoikaika kino COVID-19 e pili ana i ka ulu ʻana o ka epidemiology a me nā hōʻike e pili ana i ka emi ʻana o ka pale i ka manawa. ʻO kahi pūʻulu kumu piha me kahi kano kano mRNA COVID-19 ke hoʻomau nei ka ʻōlelo aʻoaʻo mua, a pono e hāʻawi ʻia i nā poʻe a pau o ka pūʻulu makahiki ʻae ʻia me ka ʻole o ka contraindications i ka maʻi. Ke hana nei ʻo NACI i nā ʻōlelo aʻoaʻo e pili ana i ka booster doses no kēlā mau makahiki 18 a ʻoi aʻe inā ma kahi o 6 mau mahina i hala mai kā lākou papahana mua.

Ma ke ʻano kikoʻī, ʻōlelo ʻo NACI e hāʻawi ʻia nā mea hoʻoikaika o ka mRNA COVID-19 i kēia mau heluna: nā pākeke 50 mau makahiki a ʻoi paha; nā mākua e noho ana i loko o nā hale mālama lōʻihi no ka poʻe ʻelemakule a i ʻole kahi noho hui ʻē aʻe e mālama ai i ka poʻe ʻelemakule; nā mākua i loko a i ʻole mai ka First Nations, Inuit a i ʻole nā kaiāulu Métis; ka poʻe i loaʻa i ka pūʻulu o ka lāʻau lapaʻau viral vector i hoʻopau ʻia me nā lāʻau lapaʻau viral vector wale nō; a me nā limahana mālama ola kino ma mua o nā mākua (e pili pono ana i nā maʻi) a hiki ke hāʻawi ʻia i nā mākua 18 a 49 mau makahiki.

ʻO ka hoʻopiha ʻana i ka papa hana o ka lāʻau lapaʻau ʻelua no ka poʻe kūpono. Hāʻawi ka papahana mua i ka pale maikaʻi loa mai ka hale maʻi a me ka make no ka wā lōʻihi, ʻoiai ke hāʻawi ʻia ka lua ma kahi o 8 mau pule ma hope o ka maʻa mua. Hoʻihoʻi hou ka booster i ka pale i emi iho i ka manawa, e ʻae ana i ka pale ʻoi aku ka lōʻihi e kōkua i ka hōʻemi ʻana i ka maʻi, ka hoʻoili ʻana, a ma kekahi mau heluna, nā maʻi koʻikoʻi. Ua nānā hou ʻo NACI i ka ʻikepili i ka poʻe i loaʻa i ka maʻi ma mua a hoʻomau i ka ʻōlelo ʻana e loaʻa iā lākou kahi papa hana like me ka poʻe i loaʻa ʻole i ka maʻi ma mua. ʻO ka hoʻopaʻa ʻana ma hope o ka maʻi e hāʻawi i ka palekana hilinaʻi a lōʻihi loa e kūʻē iā SARS-CoV 2.

E like me ka mea i hōʻike ʻia ma kā mākou ʻōlelo ma mua e pili ana i nā mea hoʻoikaika COVID-19, e hoʻomau nā panalāʻau a me nā panalāʻau ma luna o ka ʻōlelo aʻoaʻo a NACI e hoʻokō pono i nā hoʻolaha hoʻomaʻamaʻa kūpono i ko lākou mau ʻāina. Ua paʻa mākou e hoʻohana maikaʻi i nā kano COVID-19 e pili ana i nā hōʻike hou loa a me nā ʻōlelo aʻo loea e hiki ai i kā mākou mau pahuhopu koʻikoʻi o ka hōʻemi ʻana i nā maʻi koʻikoʻi a me nā make holoʻokoʻa ʻoiai e mālama ana i ka hiki o ka ʻōnaehana olakino, a me ka hōʻemi ʻana i ka hoʻouna ʻana e pale i nā heluna kiʻekiʻe. I ka ʻōlelo aʻo e hāʻawi i nā mea hoʻoikaika no nā pākeke e noho ana ma Kanada, ke hana nei mākou i kahi ala e mālama ai a hōʻoia mākou e pale aku i nā heluna pilikia a me kā mākou ʻōnaehana olakino.

Ua hoʻokuʻu pū ʻo NACI i nā alakaʻi hou e pili ana i ka hoʻohana ʻana i ka maʻi mRNA e pili ana i ka ʻikepili kiaʻi hou loa mai Kanada, ʻAmelika a me ʻEulopa, e pili ana i nā hihia koʻikoʻi o ka myocarditis a me ka pericarditis ma hope o ka hoʻopaʻa ʻana. No ka hoʻohaʻahaʻa i ka hopena o ka myocarditis a i ʻole pericarditis, i ʻike ʻia he ʻoi aku ka kiʻekiʻe no Moderna ma mua o Pfizer i nā ʻōpio a me nā ʻōpio ʻōpio, ʻōlelo ʻo NACI e makemake ʻia ka huahana Pfizer-BioNTech 30 mcg no ka moʻolelo mua i kēlā mau makahiki 12 a 29. makahiki. Manaʻo ʻia he 8 mau pule ma waena o ka maʻi mua a me ka lua, no ka mea, ʻoi aku ka liʻiliʻi o ka myocarditis ma mua o nā manawa pōkole a hiki ke hopena i ka pale ʻana. Ua hōʻike pū ʻo NACI e makemake paha ka huahana Pfizer-BioNTech 30 mcg no ka nui o ka booster i kēlā mau makahiki 18 a 29 mau makahiki. ʻAʻole pono e hopohopo ka poʻe ʻōpio a me nā poʻe ʻōpio 12 a 29 mau makahiki i loaʻa i hoʻokahi a i ʻole ʻelua mau puʻupuʻu o ka lāʻau lapaʻau Moderna ma mua o kekahi mau pule i hala aku nei, no ka mea, he kakaikahi ka pilikia o ka myocarditis/pericarditis me kēia kano a he ʻino. Hiki ke hana ma'amau i loko o ho'okahi pule ma hope o ka ho'opa'a 'ana. ʻAʻole pono e hoʻopaneʻe ʻia ka lāʻau lapaʻau inā ʻaʻole i loaʻa ka huahana i makemake ʻia i ka manawa o ka lāʻau lapaʻau.

Ua hōʻike ʻia nā maʻi o ka myocarditis a/a i ʻole pericarditis ma hope o ka hoʻopaʻa ʻana i ka mRNA COVID-19 ma kahi o 1 i 50,000 a i ʻole 0.002% o nā kau i lawelawe ʻia. ʻO ka ʻike ʻana i nā hanana like ʻole e like me kēia he hōʻike i ka maikaʻi o kā mākou ʻōnaehana nānā ma Kanada a me ka honua. Hiki mai nā hanana ʻino (nā hopena ʻaoʻao) ma hope o ka hoʻomaʻamaʻa COVID-19, a ʻo ka hapa nui he maʻalahi a loaʻa ka ʻeha ma kahi o ka injection a i ʻole kahi kuni liʻiliʻi. ʻOi aku ma mua o 60 miliona mau kau o kahi kano COVID-19 i lawelawe ʻia a hiki i kēia lā ma Kanada, me nā hopena koʻikoʻi i koe ʻole loa (0.011% o nā ʻano āpau i lawelawe ʻia). Ke hoʻomau nei nā haʻawina nānā, me ka poʻe mai Kanada mai, ʻo nā maʻi mRNA i ʻae ʻia e hopena i ka hopena o ka lāʻau lapaʻau kiʻekiʻe, ʻoi loa i ka maʻi koʻikoʻi. ʻO kekahi mau haʻawina, ʻo ia hoʻi ka poʻe ma Kanada, e hōʻike ana ua hoʻokomo ka maʻi kano Moderna i kahi pane ʻoi aku ka kiʻekiʻe o ka pale ʻana e hopena i ka hopena ʻoi aku ka lōʻihi o ka lōʻihi o ka hoʻohālikelike ʻana i ka kano Pfizer-BioNTech COVID-19.

Hoʻokipa nā Luna Lapaʻau Nui o Kanada i ka nānā ʻana o NACI a mahalo iā lākou no ka hāʻawi ʻana i kā lākou mau manaʻo hou. I kā mākou ʻōlelo mua e pili ana i ka pilikia o ka myocarditis a me ka pericarditis ma hope o ka hoʻopaʻa ʻana COVID-19, ua noʻonoʻo nā Luna Nui o ke Ola i ke koʻikoʻi o ka hana ʻana i ka palekana i mea nui i ka hoʻolālā akahele o kā mākou ʻōlelo aʻo a me nā papahana kano a e hoʻomau mākou e hana i kēlā a e haʻi i nā ʻike i ka lehulehu Kanada. E hoʻomau mākou i ka hoʻohana ʻana i nā hōʻike e kōkua i ka hoʻolālā ʻana i nā hoʻolālā e hiki ke hōʻemi i nā pilikia a ʻoi aku ka lōʻihi o ka manawa.

ʻIke mākou he nīnau paha nā poʻe ma Kanada e pili ana i nā ʻōlelo aʻoaʻo hou e pili ana i ka hoʻohana ʻana i nā mea hoʻoikaika COVID-19 a me nā kano mRNA, e pili ana i ko lākou mau makahiki, ke kūlana kano a me nā kūlana kūʻokoʻa. Pono nā kānaka e noʻonoʻo pono i nā pōmaikaʻi o nā lāʻau lapaʻau āpau i ʻae ʻia no ka hoʻohana ʻana ma Kanada i ka pale ʻana i nā maʻi koʻikoʻi, ka haukapila a me ka make mai COVID-19. Pono nā kānaka e ʻimi i ka ʻike mai kā lākou mea mālama ola kino a i ʻole nā luna olakino o ka lehulehu inā he nīnau lākou e pili ana i nā huahana kano i kūpono iā lākou.

Ke hoʻomau nei nā pōmaikaʻi o nā kano i ʻae ʻia ma Kanada ma mua o nā pilikia. Hoʻopili ʻia ka maʻi me ka maʻi maʻi e hoʻokau ai i ka COVID-19 i nā ʻano hoʻopiʻi like ʻole e hiki ke hopena i nā hale hoʻokipa a / a i ʻole ka make. ʻO ka myocarditis kekahi o nā hoʻopiʻi ʻike ʻia o ka maʻi COVID-19, me ka nui o nā pilikia ma hope o ka maʻi ma mua o ka maʻi maʻi. Kōkua ka lāʻau lapaʻau i ka pale ʻana i kēia mau hoʻopiʻi āpau a, hui pū ʻia me nā ʻano olakino olakino ʻē aʻe e like me ka hoʻohana ʻana i ka mask, ka pale ʻana i nā wahi ākea, ka hoʻonui ʻana i ka ventila a me ka hele kino, hiki ke kōkua iā mākou e hauʻoli i nā mea a mākou e aloha nui ai. Ke hoʻomau nei nā Luna Lapaʻau Nui o Kanada i ka paipai ʻana i nā poʻe āpau e loaʻa i ka lāʻau lapaʻau no ka pale ʻana iā lākou iho a me ka poʻe a puni lākou.

ʻO ka ʻaha kūkā o nā Luna Lapaʻau Nui o ke Ola e komo pū ana ka Luna Lapaʻau Nui o ke Ola mai kēlā me kēia panalāʻau a me ka ʻāina ʻāina, ʻo ke poʻo nui o ka Public Health Officer o Canada, ke Kauka Lapaʻau Nui o Health Canada, ka Luna Lapaʻau Nui o ka Public Health of Indigenous Services Canada, ke Aliʻi. Luna Lapaʻau mai ka First Nations Health Authority, a me nā lālā ex-officio mai nā keʻena aupuni federal.

He aha e lawe ʻia mai kēia ʻatikala:

To mitigate the risk of myocarditis or pericarditis, which has been found to be somewhat higher for Moderna than Pfizer in adolescents and young adults, NACI recommends that the Pfizer-BioNTech 30 mcg product is preferred for the primary series in those 12 to 29 years of age.
However, the recent emergence of the Omicron variant is a reminder that the COVID-19 pandemic is not over and that we live in a global community.
A complete primary series with an mRNA COVID-19 vaccine continues to be the first recommendation, and should be offered to everyone in the authorized age group without contraindications to the vaccine.